Journal of Hematology & Oncology

Article	Citations
1-year survival in haemophagocytic lymphohistiocytosis: a nationwide cohort study from England 2003–2018	796
Novel natural killer cell-based therapies for hematologic and solid malignancies: latest updates from ASCO 2024	459
The small inhibitor WM-1119 effectively targets KAT6A-rearranged AML, but not KMT2A-rearranged AML, despite shared KAT6 genetic dependency	458
Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial	457
HRAS is a therapeutic target in malignant chemo-resistant adenomyoepithelioma of the breast	453
Identification of restrictive molecules involved in oncolytic virotherapy using genome-wide CRISPR screening	436
Retraction Note: m6A mRNA methylation initiated by METTL3 directly promotes YAP translation and increases YAP activity by regulating the MALAT1-miR-1914-3p-YAP axis to induce NSCLC drug resistance and	395
Mapping the cell therapy landscape: insights into clinical trials and regulatory advances in China	361
CAR-T therapy alters synthesis of platelet-activating factor in multiple myeloma patients	343
Proteasome inhibition enhances oncolytic reovirus therapy in multiple myeloma independently of its direct cytotoxic effects	337
Comprehensive molecular characterization of lung tumors implicates AKT and MYC signaling in adenocarcinoma to squamous cell transdifferentiation	329
Cancer vaccines: current status and future directions	322
KRAS mutation detection by liquid biopsy for pancreatic ductal adenocarcinoma	297
Allogeneic hematopoietic cell transplantation with cord blood versus mismatched unrelated donor with post-transplant cyclophosphamide in acute myeloid leukemia	288
WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associ	277
The Association of Agent Orange Exposure with the progression of monoclonal gammopathy of undetermined significance to multiple myeloma: a population-based study of Vietnam War Era Veterans	268
Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy	267
Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies	261
Landscape of biallelic DNMT3A mutant myeloid neoplasms	250
Efficacy and safety of CPX-351 versus 7 + 3 chemotherapy by European LeukemiaNet 2017 risk subgroups in older adults with newly diagnosed, high-risk/secondary AML: post hoc analysis of a randomized, p	242
Evidence of SARS-CoV-2 spike protein on retrieved thrombi from COVID-19 patients	234
Long non-coding RNAs in brain tumors: roles and potential as therapeutic targets	233
Modulating tumor infiltrating myeloid cells to enhance bispecific antibody-driven T cell infiltration and anti-tumor response	227
Hypertension and incident cardiovascular events after next-generation BTKi therapy initiation	224
Toll-like receptors and toll-like receptor-targeted immunotherapy against glioma	217

A novel lncRNA ROPM-mediated lipid metabolism governs breast cancer stem cell properties	211
Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2	205
Long noncoding RNA Smyca coactivates TGF-β/Smad and Myc pathways to drive tumor progression	204
Integrated proteogenomic analysis revealed the metabolic heterogeneity in noncancerous liver tissues of patients with hepatocellular carcinoma	193
Comparative analysis of cancer cell responses to targeted radionuclide therapy (TRT) and external beam radiotherapy (EBRT)	184
Personalized nanovaccines for treating solid cancer metastases	183
Recent advances in therapeutic strategies for non-small cell lung cancer	182
Ferroptosis: principles and significance in health and disease	174
NBAS, a gene involved in cytotoxic degranulation, is recurrently mutated in pediatric hemophagocytic lymphohistiocytosis	173
IL-15-secreting CAR natural killer cells directed toward the pan-cancer target CD70 eliminate both cancer cells and cancer-associated fibroblasts	173
Overcome the challenge for intratumoral injection of STING agonist for pancreatic cancer by systemic administration	159
Hypoxia-induced exosomal circPDK1 promotes pancreatic cancer glycolysis via c-myc activation by modulating miR-628-3p/BPTF axis and degrading BIN1	155
Targeting CD47 for cancer immunotherapy	155
Super-enhancer hijacking LINC01977 promotes malignancy of early-stage lung adenocarcinoma addicted to the canonical TGF-β/SMAD3 pathway	153
Cancer-associated fibroblast-specific lncRNA LINC01614 enhances glutamine uptake in lung adenocarcinoma	151
Epigenetic regulation of diverse cell death modalities in cancer: a focus on pyroptosis, ferroptosis, cuproptosis, and disulfidptosis	151
Outcomes of patients with acute myeloid leukemia and bone marrow fibrosis	150
Similar outcomes following non-first-degree and first-degree related donor haploidentical hematopoietic cell transplantation for acute leukemia patients in complete remission: a study from the Global	148
Treatment with soluble CD24 attenuates COVID-19-associated systemic immunopathology	148
Low titers of SARS-CoV-2 neutralizing antibodies after first vaccination dose in cancer patients receiving checkpoint inhibitors	147
Correction: The long and short non-coding RNAs modulating EZH2 signaling in cancer	147
Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient?	136
Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation	135
The developing landscape of combinatorial therapies of immune checkpoint blockade with DNA damage repair inhibitors for the treatment of breast and ovarian cancers	134
Kynurenine derivative 3-HAA is an agonist ligand for transcription factor YY1	130
3D chromatin architecture and transcription regulation in cancer	128
Non-invasive diagnosis of esophageal cancer by a simplified circulating cell-free DNA methylation assay targeting OTOP2 and KCNA3: a double-blinded, multicenter, prospective study	127
Emerging strategies in targeting tumor-resident myeloid cells for cancer immunotherapy	127
Identifying long-term survivors and those at higher or lower risk of relapse among patients with cytogenetically normal acute myeloid leukemia using a high-dimensional mixture cure model	126
Unraveling the roles and mechanisms of mitochondrial translation in normal and malignant hematopoiesis	125
Development of a novel combined nomogram model integrating deep learning-pathomics, radiomics and immunoscore to predict postoperative outcome of colorectal cancer lung metastasis patients	124
First-in-human phase I study of CLL-1 CAR-T cells in adults with relapsed/refractory acute myeloid leukemia	121
Small RNA modifications: regulatory molecules and potential applications	119
Recent advances in targeted strategies for triple-negative breast cancer	119
Therapeutic roles of mesenchymal stem cell-derived extracellular vesicles in cancer	117
A single-cell transcriptomic map of the murine and human multiple myeloma immune microenvironment across disease stages	116
Development and validation of the post-CAR prognostic index for large B-cell lymphoma patients after CAR-T progression in third or later line treatment	113
A proteolysis-targeting chimera molecule selectively degrades ENL and inhibits malignant gene expression and tumor growth	113
Osteosarcoma with cell-cycle and fibroblast growth factor genomic alterations: case report of Molecular Tumor Board combination strategy resulting in long-term exceptional response	113
Recent advances in sarcoma therapy: new agents, strategies and predictive biomarkers	112
Correction: Non-invasive diagnosis of esophageal cancer by a simplified circulating cell-free DNA methylation assay targeting OTOP2 and KCNA3: a double-blinded, multicenter, prospective study	111
Proteasome inhibition enhances the anti-leukemic efficacy of chimeric antigen receptor (CAR) expressing NK cells against acute myeloid leukemia	109
Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure	108
COVID-19 in pediatric cancer patients is associated with treatment interruptions but not with short-term mortality: a Polish national study	107
GAS6-based CAR-T cells exhibit potent antitumor activity against pancreatic cancer	107
Treatment outcomes for newly diagnosed, treatment-naïve TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis	106
Novel potent molecular glue degraders against broad range of hematological cancer cell lines via multiple neosubstrates degradation	106
LCN2 secreted by tissue-infiltrating neutrophils induces the ferroptosis and wasting of adipose and muscle tissues in lung cancer cachexia	103
Genotype–phenotype associations within the Li-Fraumeni spectrum: a report from the German Registry	103
Methyltransferase-like proteins in cancer biology and potential therapeutic targeting	102

A single-cell and spatially resolved atlas of human osteosarcomas	101
Asciminib add-on to imatinib demonstrates sustained high rates of ongoing therapy and deep molecular responses with prolonged follow-up in the ASC4MORE study	101
hUC-EVs-ATO reduce the severity of acute GVHD by resetting inflammatory macrophages toward the M2 phenotype	101
Deciphering mechanisms of immune escape to inform immunotherapeutic strategies in multiple myeloma	100
Targeting cuproptosis for cancer therapy: mechanistic insights and clinical perspectives	100
Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts	100
Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies	98
Fibrinogen-like protein 1 (FGL1): the next immune checkpoint target	98
Chemo-free treatment of adult patients with Ph-positive acute lymphoblastic leukemia: latest updates from the 2023 ASH annual meeting	97
HLA alleles associated with asparaginase hypersensitivity in Chinese children	96
TET2 and DNMT3A mutations and exceptional response to 4′-thio-2′-deoxycytidine in human solid tumor models	93
Preclinical evaluation of combination nemtabrutinib and venetoclax in chronic lymphocytic leukemia	93
Correction: Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee	93
Metabolic landscapes in sarcomas	92
Circular RNAs: characteristics, biogenesis, mechanisms and functions in liver cancer	91
Prognostic and therapeutic implications of measurable residual disease in acute myeloid leukemia	90
Targeting Claudin-18.2 for cancer therapy: updates from 2024 ASCO annual meeting	88
Electrostatic anti-CD33-antibody–protamine nanocarriers as platform for a targeted treatment of acute myeloid leukemia	88
The roles of GTPase-activating proteins in regulated cell death and tumor immunity	86
The functional and clinical roles of liquid biopsy in patient-derived models	86
Echinomycin as a promising therapeutic agent against KSHV-related malignancies	86
Innate immune mediator, Interleukin-1 receptor accessory protein (IL1RAP), is expressed and pro-tumorigenic in pancreatic cancer	86
JMJD4-demethylated RIG-I prevents hepatic steatosis and carcinogenesis	85
C3G promotes bone marrow adipocyte expansion and hematopoietic regeneration after myeloablation by enhancing megakaryocyte niche function	84
A clinical study of autologous chimeric antigen receptor macrophage targeting mesothelin shows safety in ovarian cancer therapy	83
CD20 xCD3 bispecific antibodies for large B cell lymphoma: latest updates from 2024 ASH annual meeting	82
Worked to the bone: antibody-based conditioning as the future of transplant biology	82
Cancer-associated fibroblast heterogeneity is associated with organ-specific metastasis in pancreatic ductal adenocarcinoma	82
Tucidinostat plus pediatric-inspired chemotherapy for newly diagnosed adult ETP-ALL/LBL: a single-arm, phase 2 trial	81
Intratumor heterogeneity: the hidden barrier to immunotherapy against MSI tumors from the perspective of IFN-γ signaling and tumor-infiltrating lymphocytes	81
New immunotherapy strategies for patients with sarcomas: highlights from the 2023 ASCO annual meeting	78
Lenvatinib and immune-checkpoint inhibitors in hepatocellular carcinoma: mechanistic insights, clinical efficacy, and future perspectives	78
Clinical experiences with venetoclax and other pro-apoptotic agents in lymphoid malignancies: lessons from monotherapy and chemotherapy combination	77
Iparomlimab (QL1604) in patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) unresectable or metastatic solid tumors: a pivotal, single-arm, multicenter, phase II	77
Targeting extracellular matrix stiffness and mechanotransducers to improve cancer therapy	76
LncRNA Snhg6 regulates the differentiation of MDSCs by regulating the ubiquitination of EZH2	76
The long and short non-coding RNAs modulating EZH2 signaling in cancer	75
Challenges and new technologies in adoptive cell therapy	75
Gastric cancer treatment: recent progress and future perspectives	72
Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives	72
Targeting GPRC5D for multiple myeloma therapy	69
Reduced-dose chemotherapy and blinatumomab as induction treatment for newly diagnosed Ph-negative B-cell precursor acute lymphoblastic leukemia: a phase 2 trial	67
GVHD occurrence does not reduce AML relapse following PTCy-based haploidentical transplantation: a study from the ALWP of the EBMT	65
Long-term survival with donor CD19 CAR-T cell treatment for relapsed patients after allogeneic hematopietic stem cell transplantation	65
SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders	63
Genomic characterization of AML with aberrations of chromosome 7: a multinational cohort of 519 patients	63
m6A regulators as predictive biomarkers for chemotherapy benefit and potential therapeutic targets for overcoming chemotherapy resistance in small-cell lung cancer	62
RAS signaling in carcinogenesis, cancer therapy and resistance mechanisms	61
Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation	61
First-in-human phase I/Ib study of QL1706 (PSB205), a bifunctional PD1/CTLA4 dual blocker, in patients with advanced solid tumors	61
LncRNA-PACERR induces pro-tumour macrophages via interacting with miR-671-3p and m6A-reader IGF2BP2 in pancreatic ductal adenocarcinoma	61
Metabolic reprogramming in the tumor microenvironment of liver cancer	61
METTL16 promotes liver cancer stem cell self-renewal via controlling ribosome biogenesis and mRNA translation	60
Amplification of spatially isolated adenosine pathway by tumor–macrophage interaction induces anti-PD1 resistance in hepatocellular carcinoma	60
Targeting regulated cell death (RCD) with small-molecule compounds in triple-negative breast cancer: a revisited perspective from molecular mechanisms to targeted therapies	59
CD38-directed CAR-T cell therapy: a novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation	59
Applications of single-cell sequencing in cancer research: progress and perspectives	58
Mesenchymal stem/stromal cells in cancer therapy	57
Universal immunotherapeutic strategy for hepatocellular carcinoma with exosome vaccines that engage adaptive and innate immune responses	57
Correction: Immunosenescence: a key player in cancer development	56
Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study	56
A practical approach on the classifications of myeloid neoplasms and acute leukemia: WHO and ICC	56
Broadly applicable TCR-based therapy for multiple myeloma targeting the immunoglobulin J chain	56
Homogeneously high expression of CD32b makes it a potential target for CAR-T therapy for chronic lymphocytic leukemia	55
Correction: Large-scale real-life analysis of survival and usage of therapies in multiple myeloma	54
Large-scale real-life analysis of survival and usage of therapies in multiple myeloma	54
Treatment of myelodysplastic syndromes in the era of precision medicine and immunomodulatory drugs: a focus on higher-risk disease	54
Elevated plasma levels of IL-6 and MCP-1 selectively identify CML patients who better sustain molecular remission after TKI withdrawal	53
Advances in CAR-T cell therapy for hematologic and solid malignancies: latest updates from 2024 ESMO Congress	53
Replicon RNA vaccines: design, delivery, and immunogenicity in infectious diseases and cancer	53
Correction : LINC01123, a c-Myc-activated long non-coding RNA, promotes proliferation and aerobic glycolysis of non-small cell lung cancer through miR-199a-5p/c-Myc axis	53
Nanomaterials-driven in situ vaccination: a novel frontier in tumor immunotherapy	52
Circular RNA circHERC4 as a novel oncogenic driver to promote tumor metastasis via the miR-556-5p/CTBP2/E-cadherin axis in colorectal cancer	51
Considerations for the design of antibody drug conjugates (ADCs) for clinical development: lessons learned	51
Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study	49
The cGAS‒STING pathway in cancer immunity: mechanisms, challenges, and therapeutic implications	49
Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee	49
Momelotinib: an emerging treatment for myelofibrosis patients with anemia	49
Blockade of checkpoint receptor PVRIG unleashes anti-tumor immunity of NK cells in murine and human solid tumors	49
Emerging strategies to target RAS signaling in human cancer therapy	48

Myeloid-like tumor hybrid cells in bone marrow promote progression of prostate cancer bone metastasis	48
Mesenchymal stromal cells plus basiliximab, calcineurin inhibitor as treatment of steroid-resistant acute graft-versus-host disease: a multicenter, randomized, phase 3, open-label trial	48
Advances in targeting histone deacetylase for treatment of solid tumors	48
Immune checkpoint of B7-H3 in cancer: from immunology to clinical immunotherapy	48
C3aR costimulation enhances the antitumor efficacy of CAR-T cell therapy through Th17 expansion and memory T cell induction	47
Non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary versus de novo AML in first complete remission: a study from the ALWP/EBMT	47
Precision oncology in AML: validation of the prognostic value of the knowledge bank approach and suggestions for improvement	47
Correction to: HLA-A2.1-restricted ECM1-derived epitope LA through DC cross-activation priming CD8+ T and NK cells: a novel therapeutic tumour vaccine	47
Safety and efficacy of amulirafusp alfa (IMM0306), a fusion protein of CD20 monoclonal antibody with the CD47 binding domain of SIRPα, in patients with relapsed or refractory B-cell non-Hodgkin lympho	47
Retraction Note: AMLnet, A deep-learning pipeline for the differential diagnosis of acute myeloid leukemia from bone marrow smears	47
Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19: matched-paired analysis in the EPICOVIDEHA registry	46
High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status	46
Development and application of nanomaterials, nanotechnology and nanomedicine for treating hematological malignancies	46
Targeting ERRα promotes cytotoxic effects against acute myeloid leukemia through suppressing mitochondrial oxidative phosphorylation	46
Novel clinical risk stratification and treatment strategies in relapsed/refractory peripheral T-cell lymphoma	45
Crosstalk among m6A RNA methylation, hypoxia and metabolic reprogramming in TME: from immunosuppressive microenvironment to clinical application	45
The relationship between expression of PD-L1 and HIF-1α in glioma cells under hypoxia	45
A novel role of lysophosphatidic acid (LPA) in human myeloma resistance to proteasome inhibitors	44
Global status and attributable risk factors of breast, cervical, ovarian, and uterine cancers from 1990 to 2021	44
Optimizing CAR-T cell therapy for solid tumors: current challenges and potential strategies	44
Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2	44
Prognostic landscape of mitochondrial genome in myelodysplastic syndrome after stem-cell transplantation	42
Matching-adjusted indirect treatment comparison of liso-cel versus axi-cel in relapsed or refractory large B cell lymphoma	42
Post-transplant cyclophosphamide alters immune signatures and leads to impaired T cell reconstitution in allogeneic hematopoietic stem cell transplant	42
Reprogramming T cell differentiation and exhaustion in CAR-T cell therapy	41
Functions, mechanisms, and therapeutic implications of METTL14 in human cancer	41
Targeting inflammation as cancer therapy	41
Germline biallelic BRCA2 pathogenic variants and medulloblastoma: an international cohort study	41
Safety and preliminary efficacy of the Gam-COVID-Vac vaccine and outcomes of SARS-CoV-2 infection in Russian patients with genitourinary malignancies	41
Lipid metabolic reprogramming in tumor microenvironment: from mechanisms to therapeutics	41
Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy	41
Matched related transplantation versus immunosuppressive therapy plus eltrombopag for first-line treatment of severe aplastic anemia: a multicenter, prospective study	41
The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades	40
Multiscale protein networks systematically identify aberrant protein interactions and oncogenic regulators in seven cancer types	40
Regimens combining radiation and immunotherapy for cancer: latest updates from 2024 ASCO Annual Meeting	39
Immunotherapies targeting stimulatory pathways and beyond	39
Menin inhibitors for the treatment of acute myeloid leukemia: challenges and opportunities ahead	39
Correction: Dual inhibition of IGF-IR and ALK as an effective strategy to eradicate NPM-ALK+ T-cell lymphoma	39
Quality-adjusted Time Without Symptoms of disease or Toxicity (Q-TWiST) analysis of CPX-351 versus 7 + 3 in older adults with newly diagnosed high-risk/secondary AML	38
BCMA-targeted therapies for multiple myeloma: latest updates from 2024 ASH annual meeting	38
Phase II trial of daratumumab with DCEP in relapsed/refractory multiple myeloma patients with extramedullary disease	38
Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: latest updates from ASCO 2023 Annual Meeting	38
Elraglusib (9-ING-41), a selective small-molecule inhibitor of glycogen synthase kinase-3 beta, reduces expression of immune checkpoint molecules PD-1, TIGIT and LAG-3 and enhances CD8+ T cell cytolyt	37
Bispecific antibody-activated T cells enhance NK cell-mediated antibody-dependent cellular cytotoxicity	37
KAI1(CD82) is a key molecule to control angiogenesis and switch angiogenic milieu to quiescent state	37
Spatial imaging unlocks the potential of charting multiple myeloma and extramedullary disease	36
The consensus from The Chinese Society of Hematology on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation: 2021 update	36
RNA demethylase ALKBH5 in cancer: from mechanisms to therapeutic potential	36
Wnt/β-catenin signaling pathway in carcinogenesis and cancer therapy	35
Correction: Phase IB part of LOC-R01, a LOC network non-comparative randomized phase IB/II study testing R-MPV in combination with escalating doses of lenalidomide or ibrutinib for newly diagnosed pri	35
CD20 × CD3 bispecific antibodies for lymphoma therapy: latest updates from ASCO 2023 annual meeting	35
Genitourinary cancers updates: highlights from ASCO 2023	35
Anti-TGF-β/PD-L1 bispecific antibody synergizes with radiotherapy to enhance antitumor immunity and mitigate radiation-induced pulmonary fibrosis	34
Small extracellular vesicle non-coding RNAs in pancreatic cancer: molecular mechanisms and clinical implications	34
Heterodimerization of T cell engaging bispecific antibodies to enhance specificity against pancreatic ductal adenocarcinoma	34
Novel strategies for cancer immunotherapy: counter-immunoediting therapy	34
Impaired neutralisation of SARS-CoV-2 delta variant in vaccinated patients with B cell chronic lymphocytic leukaemia	34
A novel tRNA-derived fragment tRF-3022b modulates cell apoptosis and M2 macrophage polarization via binding to cytokines in colorectal cancer	32
Synergistic efficacy of simultaneous anti-TGF-β/VEGF bispecific antibody and PD-1 blockade in cancer therapy	32
Therapeutic implications of cancer gene amplifications without mRNA overexpression: silence may not be golden	31
Disruption of the sorcin‒PAX5 protein‒protein interaction induces ferroptosis by promoting the FBXL12-mediated ubiquitination of ALDH1A1 in pancreatic cancer	31
Homologous recombination deficiency (HRD) can predict the therapeutic outcomes of immuno-neoadjuvant therapy in NSCLC patients	31
Treatment-induced arteriolar revascularization and miR-126 enhancement in bone marrow niche protect leukemic stem cells in AML	31
Oral eltanexor treatment of patients with higher-risk myelodysplastic syndrome refractory to hypomethylating agents	31
Prostate cancer multiparametric magnetic resonance imaging visibility is a tumor-intrinsic phenomena	31
Novel ADCs and combination therapy in urothelial carcinoma: latest updates from the 2023 ASCO-GU Cancers Symposium	30
Randomized phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced soft-tissue sarcoma	30
Global burden of cancer and associated risk factors in 204 countries and territories, 1980–2021: a systematic analysis for the GBD 2021	30
Leveraging CD16 fusion receptors to remodel the immune response for enhancing anti-tumor immunotherapy in iPSC-derived NK cells	30
Remodeling of anti-tumor immunity with antibodies targeting a p53 mutant	29
Unraveling the triad of hypoxia, cancer cell stemness, and drug resistance	29
Involvement of inflammasomes in tumor microenvironment and tumor therapies	29
Evolving therapeutic landscape in follicular lymphoma: a look at emerging and investigational therapies	29
Recent advances in therapeutic strategies for triple-negative breast cancer	28
Non-canonical small noncoding RNAs in the plasma extracellular vesicles as novel biomarkers in gastric cancer	28
A novel tRNA-derived fragment AS-tDR-007333 promotes the malignancy of NSCLC via the HSPB1/MED29 and ELK4/MED29 axes	28
Liquid biopsy: current technology and clinical applications	28
The R-RAS2 GTPase is a signaling hub in triple-negative breast cancer cell metabolism and metastatic behavior	28
Consensus, debate, and prospective on pancreatic cancer treatments	28
Incidence, mortality, risk factors, and trends for Hodgkin lymphoma: a global data analysis	28
CXCL13 chemokine is a novel player in multiple myeloma osteolytic microenvironment, M2 macrophage polarization, and tumor progression	28
Targeting STAT3-VISTA axis to suppress tumor aggression and burden in acute myeloid leukemia	28
Therapeutic strategies in METex14 skipping mutated non-small cell lung cancer	27
Correction: Triple MAPK inhibition salvaged a relapsed post-BCMA CAR-T cell therapy multiple myeloma patient with a BRAF V600E subclonal mutation	27
PARP1-MGMT complex underpins pathway crosstalk in O6-methylguanine repair	27
CircRNA-CREIT inhibits stress granule assembly and overcomes doxorubicin resistance in TNBC by destabilizing PKR	27
PD-1 blockade immunotherapy as a successful rescue treatment for disseminated adenovirus infection after allogeneic hematopoietic stem cell transplantation	27
Recent progress on vascular endothelial growth factor receptor inhibitors with dual targeting capabilities for tumor therapy	27
Harnessing immunotherapy for brain metastases: insights into tumor–brain microenvironment interactions and emerging treatment modalities	26
The synthetic lethality of targeting cell cycle checkpoints and PARPs in cancer treatment	26
Targeting FGFR for cancer therapy	26
Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study	26
Development and characterization of NILK-2301, a novel CEACAM5xCD3 κλ bispecific antibody for immunotherapy of CEACAM5-expressing cancers	26
Venetoclax Combined with Azacitidine and Homoharringtonine in Relapsed/Refractory AML: A Multicenter, Phase 2 Trial	26
LncRNA-encoded peptides in cancer	26